Novel genomic variants influencing methotrexate delayed clearance in pediatric patients with acute lymphoblastic leukemia
Frontiers in Pharmacology · 14.11.2024 · 15
DOI: 10.3389/fphar.2024.1480657 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 14.11.2024. Verfasst von Jung Yoon Choi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Seoul National University Children's Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Methotrexate (MTX) is the primary drug used in the treatment of pediatric acute lymphoblastic leukemia (ALL). However, some patients exhibit delayed clearance of high-dose (HD) MTX, which induces severe nephrotoxicity, mucositis, hepatotoxicity, and neurotoxicity. We sought to identify relevant variants associated with delayed clearance of HD-MTX in pediatric patients with ALL.
Methods
Whole-exome sequencing of germline DNA was performed in 51 Korean pediatric patients with ALL. A total of 341 HD-MTX infusion data points from 51 patients were analyzed. MTX levels and laboratory measurements reflecting toxicity outcomes were obtained. Correlations between peak serum MTX levels at 24 h and toxicity outcomes were assessed. Analyses were performed to identify variants affecting delayed MTX clearance.
Results
The 24 h MTX level strongly correlated with the subsequent creatinine (Cr) level. Moreover, rs2229866 in contactin 2 ( CNTN2 ), rs200687372 in myotubularin Related Protein 9 ( MTMR9 ), rs777260512 in polymerase iota ( POLI ), rs16954698 in polycystic kidney disease 1-like 2 ( PKD1L2 ), rs117765468 in NSE1 Homolog, SMC5-SMC6 Complex Component ( NSMCE1 ) , and rs1800956 in endoglin ( ENG ) were identified as candidate variants associated with delayed MTX clearance. In particular, ENG rs1800956 was significantly associated with delayed MTX clearance in all analyses and PKD1L2 rs16954698 was replicated in an external dataset (phs000637.v1.p1) from the Database of Genotypes and Phenotypes (dbGaP).
Conclusion
This is the first whole-exome sequencing-based analysis of delayed MTX clearance in pediatric patients with ALL. ENG rs1800956 and PKD1L2 rs16954698 were found to be potentially influential variants associated with delayed MTX clearance. These findings provide insights into HD-MTX-induced nephrotoxicity and may contribute to reducing adverse reactions through treatment modification.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, Seoul National University Children's Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Seoul National University Cancer Research Institute, Seoul, Republic of Korea.
- Seoul National University Biomedical Informatics (SNUBI), Division of Biomedical Informatics, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Republic of Korea.
- Department of Pediatrics, Seoul Metropolitan Children's Hospital, Seoul, Republic of Korea.
- Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Zitieren
APA
Choi, J. Y., Kwon, H., Kim, H., Hong, K. T., Ma, Y., Koh, K. N., Yun, S., Yoo, K. H., Song, S. H., Im, H. J., Kim, J. H., & Kang, H. J. (2024). Novel genomic variants influencing methotrexate delayed clearance in pediatric patients with acute lymphoblastic leukemia. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1480657
Vancouver
Choi JY, Kwon H, Kim H, Hong KT, Ma Y, Koh KN, et al. Novel genomic variants influencing methotrexate delayed clearance in pediatric patients with acute lymphoblastic leukemia. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1480657
BibTeX
@article{Choi2024,
author = {Choi, Jung Yoon and Kwon, Hoshik and Kim, Hyery and Hong, Kyung Taek and Ma, Youngeun and Koh, Kyung-Nam and Yun, Sunmin and Yoo, Keon Hee and Song, Sang Hoon and Im, Ho Joon and Kim, Ju Han and Kang, Hyoung Jin},
title = {Novel genomic variants influencing methotrexate delayed clearance in pediatric patients with acute lymphoblastic leukemia},
journal = {Frontiers in Pharmacology},
year = {2024},
volume = {15},
doi = {10.3389/fphar.2024.1480657}
}
EUVIMED